Matthew H Loichinger1, Dena Towner2, Karen S Thompson3, Hyeong Jun Ahn4, Gillian D Bryant-Greenwood5. 1. Department of Obstetrics, Gynecology and Women's Health, John A. Burns School of Medicine, University of Hawaii, 1319 Punahou Street, Suite 824, Honolulu, HI 96826, USA. Electronic address: mloichin@gmail.com. 2. Department of Obstetrics, Gynecology and Women's Health, John A. Burns School of Medicine, University of Hawaii, 1319 Punahou Street, Suite 824, Honolulu, HI 96826, USA. Electronic address: dtowner@hawaii.edu. 3. Department of Pathology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA. Electronic address: karenst@hawaii.edu. 4. Biostatistics Core, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA. Electronic address: hjahn@hawaii.edu. 5. Department of Obstetrics, Gynecology and Women's Health, John A. Burns School of Medicine, University of Hawaii, 1319 Punahou Street, Suite 824, Honolulu, HI 96826, USA. Electronic address: gbg@pbrc.hawaii.edu.
Abstract
INTRODUCTION: α-klotho is an anti-aging protein, potentially important in preeclampsia (PE). Produced by kidney, brain and placenta, and by mRNA splicing is both a full-length membrane-bound and a truncated soluble protein in the circulation. The membrane-bound protein is an obligate co-receptor for fibroblast growth factor 23 (FGF23) and its action on receptor (FGFR), but ADAM proteinases also cause its shedding. The aims of this study were to investigate levels of maternal plasma, placental, and fetal membrane α-Klotho and their association with placental accelerated villous maturation (AVM) in PE. In addition, placental and membrane levels of ADAM17 and FGFR were measured in the same patients. METHODS: Maternal blood, placenta and fetal membranes from 61 women (31 with PE and 30 controls) between 32 and 40 weeks gestation were collected. Plasma α-klotho was measured by ELISA, and quantitative immunohistochemistry used for α-klotho, ADAM17 and FGFR1 in tissues. Placental AVM was histologically assessed. RESULTS: Maternal plasma levels of α-Klotho were higher in PE compared to controls (p = 0.01) and patients with the highest levels had significantly less AVM (p = 0.03). α-Klotho, ADAM17, and FGFR were all present in syncytiotrophoblast and cytotrophoblast of membranes. Between 32 and 40 weeks gestation, all placental levels decreased in controls respectively (p = 0.04, p = 0.004, p = 0.05), but not in PE. Fetal membrane levels were unchanged. DISCUSSION: Maternal plasma α-Klotho was increased in PE and its levels associated with reduced placental AVM. Changes in placental α-Klotho, ADAM17, and FGFR suggest their involvement in the pathophysiology of PE.
INTRODUCTION: α-klotho is an anti-aging protein, potentially important in preeclampsia (PE). Produced by kidney, brain and placenta, and by mRNA splicing is both a full-length membrane-bound and a truncated soluble protein in the circulation. The membrane-bound protein is an obligate co-receptor for fibroblast growth factor 23 (FGF23) and its action on receptor (FGFR), but ADAM proteinases also cause its shedding. The aims of this study were to investigate levels of maternal plasma, placental, and fetal membrane α-Klotho and their association with placental accelerated villous maturation (AVM) in PE. In addition, placental and membrane levels of ADAM17 and FGFR were measured in the same patients. METHODS: Maternal blood, placenta and fetal membranes from 61 women (31 with PE and 30 controls) between 32 and 40 weeks gestation were collected. Plasma α-klotho was measured by ELISA, and quantitative immunohistochemistry used for α-klotho, ADAM17 and FGFR1 in tissues. Placental AVM was histologically assessed. RESULTS: Maternal plasma levels of α-Klotho were higher in PE compared to controls (p = 0.01) and patients with the highest levels had significantly less AVM (p = 0.03). α-Klotho, ADAM17, and FGFR were all present in syncytiotrophoblast and cytotrophoblast of membranes. Between 32 and 40 weeks gestation, all placental levels decreased in controls respectively (p = 0.04, p = 0.004, p = 0.05), but not in PE. Fetal membrane levels were unchanged. DISCUSSION: Maternal plasma α-Klotho was increased in PE and its levels associated with reduced placental AVM. Changes in placental α-Klotho, ADAM17, and FGFR suggest their involvement in the pathophysiology of PE.
Authors: C M Salafia; J C Pezzullo; J A López-Zeno; S Simmens; V K Minior; A M Vintzileos Journal: Am J Obstet Gynecol Date: 1995-10 Impact factor: 8.661
Authors: M Kuro-o; Y Matsumura; H Aizawa; H Kawaguchi; T Suga; T Utsugi; Y Ohyama; M Kurabayashi; T Kaname; E Kume; H Iwasaki; A Iida; T Shiraki-Iida; S Nishikawa; R Nagai; Y I Nabeshima Journal: Nature Date: 1997-11-06 Impact factor: 49.962
Authors: Autumn J Broady; Matthew H Loichinger; Hyeong Jun Ahn; Philip M C Davy; Richard C Allsopp; Gillian D Bryant-Greenwood Journal: Placenta Date: 2016-12-18 Impact factor: 3.481
Authors: Andrew D Franklin; Juanita Saqibuddin; Kelli Stephens; Robert Birkett; Lily Marsden; Linda M Ernst; Karen K Mestan Journal: Placenta Date: 2019-08-30 Impact factor: 3.481
Authors: Andrew M South; Hossam A Shaltout; TanYa M Gwathmey; Elizabeth T Jensen; Patricia A Nixon; Debra I Diz; Mark C Chappell; Lisa K Washburn Journal: J Clin Hypertens (Greenwich) Date: 2020-05-31 Impact factor: 3.738
Authors: Yi Zhu; Larissa G P Langhi Prata; Erin O Wissler Gerdes; Jair Machado Espindola Netto; Tamar Pirtskhalava; Nino Giorgadze; Utkarsh Tripathi; Christina L Inman; Kurt O Johnson; Ailing Xue; Allyson K Palmer; Tingjun Chen; Kalli Schaefer; Jamie N Justice; Anoop M Nambiar; Nicolas Musi; Stephen B Kritchevsky; Jun Chen; Sundeep Khosla; Diana Jurk; Marissa J Schafer; Tamar Tchkonia; James L Kirkland Journal: EBioMedicine Date: 2022-03-13 Impact factor: 11.205
Authors: Germán Iñiguez; Pedro Gallardo; Juan Jose Castro; Rene Gonzalez; Mirna Garcia; Elena Kakarieka; Sebastian San Martin; Maria Cecilia Johnson; Verónica Mericq; Fernando Cassorla Journal: Front Endocrinol (Lausanne) Date: 2019-01-15 Impact factor: 5.555